An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib

被引：1
|
作者：
Hu, X.
Wang, L. P.
Zhang, Q. L.
Zhang, J.
Guo, H. Y.
Sun, S.
Wang, B. Y.
Jia, Z.
Shao, Z. M.
Wang, Z. H.
机构：
[1] Fudan Univ, Ctr Canc, Shanghai 200433, Peoples R China
[2] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[4] Fudan Univ, Dept Breast Surg, Inst Canc, Shanghai 200433, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
541
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A MAP for PI3K activation on endosomes
    Batrouni, Alex G.
    Baskin, Jeremy M.
    NATURE CELL BIOLOGY, 2020, 22 (11) : 1292 - 1294
  • [42] PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.
    Ma, Xiaoju Max
    Du, Changchun
    Sun, Laura
    Shi, Xiaoyan
    Friedman, Lori
    Doman, David
    Ebens, Allen J.
    BLOOD, 2009, 114 (22) : 437 - 437
  • [43] Evaluation of the PI3K pathway in peripheral t-cell lymphoma
    Lim, S. T.
    Nairismagi, M-L.
    Tan, S. H.
    Thit, E. E.
    Politz, O.
    Liu, N.
    Ong, C. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL)
    Holmes, Frankie Ann
    Ramos, Corinne
    Hoke, Nicholas N.
    Levin, Maren K.
    Espina, Virginia A.
    Liotta, Lance A.
    Wang, Kai
    Palma, Norma Alonzo
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
    Rodriguez-Freixinos, Victor
    Ruiz-Pace, Fiorella
    Farinas-Madrid, Lorena
    Garrido-Castro, Ana Christina
    Villacampa, Guillermo
    Nuciforo, Paolo
    Vivancos, Ana
    Dienstmann, Rodrigo
    Oaknin, Ana
    ESMO OPEN, 2019, 4 (02)
  • [46] ALK overexpression is associated with activation of PI3K/AKT signaling pathway in PTC
    Bu, Rong
    Prabhakaran, Sarita
    Beg, Shaham
    Jehan, Zeenath
    Siraj, Abdul K.
    Ahmed, Maqbool
    Hussain, Azhar
    Alsobhi, Saif A.
    Al-Dayel, Fouad
    Uddin, Shahab
    Al-Kuraya, Khawla S.
    CANCER RESEARCH, 2015, 75
  • [47] Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective
    Lucinda J. Berglund
    Journal of Clinical Immunology, 2024, 44
  • [48] Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
    O Lindblad
    E Cordero
    A Puissant
    L Macaulay
    A Ramos
    N N Kabir
    J Sun
    J Vallon-Christersson
    K Haraldsson
    M T Hemann
    Å Borg
    F Levander
    K Stegmaier
    K Pietras
    L Rönnstrand
    J U Kazi
    Oncogene, 2016, 35 : 5119 - 5131
  • [49] Strictosamide promotes wound healing through activation of the PI3K/AKT pathway
    Ming, Gu-xu
    Liu, Jun-yan
    Wu, Yu-huang
    Li, Li-yan
    Ma, Xin-yue
    Liu, Pei
    Pan, Yi-peng
    He, Xiao-ning
    Li, Yong-hui
    HELIYON, 2024, 10 (09)
  • [50] Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
    Lindblad, O.
    Cordero, E.
    Puissant, A.
    Macaulay, L.
    Ramos, A.
    Kabir, N. N.
    Sun, J.
    Vallon-Christersson, J.
    Haraldsson, K.
    Hemann, M. T.
    Borg, A.
    Levander, F.
    Stegmaier, K.
    Pietras, K.
    Ronnstrand, L.
    Kazi, J. U.
    ONCOGENE, 2016, 35 (39) : 5119 - 5131
12345